Not specifiedRegulatory Approvalregulatorymid-term

FDA Submission Status Update for ANDA220055 by MSN Laboratories

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:31:35 PM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The submission of ANDA220055 by MSN Laboratories represents a significant step in the generic drug market, which could alter competitive dynamics. Monitoring this application is crucial for understanding potential impacts on pricing and market share within the relevant therapeutic area. Regulatory context from FDA (Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process) supports the near-term read. Assessment grounded in 17 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should monitor the progress of this application as it may impact market dynamics and pricing strategies. The strongest clinical anchor is Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia (ClinicalTrials.gov), moderate corpus alignment. In Not specified, 5 regulatory and 2 competitive items passed relevance filtering for MSN Laboratories.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Approves Veklury as First Treatment for COVID-19. The submission indicates MSN Laboratories is advancing in the generic drug market, potentially increasing competition in the relevant therapeutic area.

Regulatory Outlook

Regulatory risk is concentrated around Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The standard review priority indicates a typical timeline for approval, but the outcome will be critical for market positioning and compliance for competitors.

Key Risks

Elevated medium regulatory exposure for MSN Laboratories could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, ANDA220055 could lead to increased competition, potentially driving down prices and affecting revenue for existing products in the market.
Portfolio teams should monitor the progress of this application as it may impact market dynamics and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Follow up on the review timeline and any potential approval outcomes for ANDA220055.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — TRUTAKNA (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LUMVOA (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Animated Videos and Therapeutic Play Methods on Emotional Expression, Fear and Anxiety in Children Aged 4-8 Years During the Throat Swab Procedure
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization of Nociception Phenotype in Individuals With Intellectual Disability
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Phytotherapeutics self-microemulsifying systems in pellet dosage form for enhanced intestinal drug delivery: formulation, stability, and in-vivo performance.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

MSN Laboratories
therapeutic area competitors

Commercial impact

medium

If approved, ANDA220055 could lead to increased competition, potentially driving down prices and affecting revenue for existing products in the market.

Regulatory impact

medium

The standard review priority indicates a typical timeline for approval, but the outcome will be critical for market positioning and compliance for competitors.

What to watch

Follow up on the review timeline and any potential approval outcomes for ANDA220055.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.